OCALIVA Treatment Monitoring

It May Help to Check in on Your Patients at Critical Time Points

  • REMIND patients that reductions in alkaline phosphatase may occur as early as the first 2 weeks of treatment (biochemical improvement may take longer for some patients); an important reason to stay on OCALIVA.1

    ASSESS for pruritus, as it may start within the first 2 weeks of treatment. If a patient is having severe pruritus, follow the Management of Patients with Intolerable Pruritus.12 weeks

    2 weeks
  • CONTINUE
    to evaluate for pruritus and other side effects; encourage patients by reminding them of the importance of alkaline phosphatase reductions.11 month

    1 month
  • EVALUATE
    response and tolerability to see if the patient is appropriate for titration to the 10 mg dose.13 months

    3 months
  • PERFORM
    liver monitoring testing, per AASLD guidelines and your clinical judgment.2 Also continue checking for potential side effects.3 months

    3 months
  • Continue ongoing lipid monitoring per standard of care.

Download the monitoring timeline

Continue ongoing lipid monitoring per standard of care.

Start Patients on OCALIVA

Download the Enrollment Form


Start Patients on OCALIVA

For help enrolling:
1-844-622-4278

Start Patients on OCALIVA

Interconnect® Enrollment Form

Download the Enrollment Form

For help enrolling: 1-844-622-4278

AASLD, American Association for the Study of Liver Diseases.
 

OCALIVA obeticholic acid OCALIVA obeticholic acid

Enroll for updates

Get the emails you want about OCALIVA:

  • You choose the topics
  • Content intended for US healthcare professionals

REGISTER FOR UPDATES

Register for Updates

*Required fields. Invalid entry. Please try again.

First name required
Last name required
Email required
Specialty Profession required


REGISTER


 

Thank you for your interest

You can expect a confirmation email shortly to set your preferences.

References:

  1. OCALIVA [package insert]. New York, NY: Intercept Pharmaceuticals, Inc.; 2017.
  2. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. Primary biliary cirrhosis. Hepatology. 2009;50(1):291-308.
OCALICA obeticholic acid

Enroll for updates

REGISTER FOR UPDATES

Register for Updates

*Required fields. Invalid entry. Please try again.

First name required
Last name required
Email required
Specialty Profession required


REGISTER


 

Thank you for your interest

You can expect a confirmation email shortly to set your preferences.

OCALIVA® (obeticholic acid)

Patient Assistance: 1-844-622-4278

This site is intended for US healthcare professionals only Home Visit Patient Site Prescribing Information Important Safety Information

Patient Assistance:
1-844-622-4278